Please assess the completion status of the following clinical trial:

Trial Title: Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have histologically or cytologically confirmed recurrent epithelial ovarian cancer, fallopian tube cancer, or peritoneal cancer.~2. Patients who have platinum-resistant disease (defined as having relapsed within 6 months of her last platinum-containing regimen)~3. Patients who have underwent chemotherapy of either weekly paclitaxel + bevacizumab, topotecan + bevacizumab, pegylated liposomal doxorubicin + bevacizumab in 2nd line or 3rd line chemotherapy.~Exclusion Criteria:~1. Patients with previous treatment with bevacizumab.~2. Patients who received bevacizumab combination therapy in 4th line or more chemotherapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Weekly paclitaxel + bevacizumab (Type: None): None
- Topotecan + bevacizumab (Type: None): None
- Pegylated liposomal doxorubicin + bevacizumab (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).